847: Institutional Variability in Predictive Accuracy of Urinary Cytology for Prediction of Transitional Cell Carcinoma Recurrence

2005 ◽  
Vol 173 (4S) ◽  
pp. 230-230
Author(s):  
Serge Benayoun ◽  
Shahrokh F. Shariat ◽  
Paul Perrotte ◽  
Martin G. Friedrich ◽  
Craig D. Zippe ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Predictive Accuracy ◽  
Transitional Cell ◽  
Urinary Cytology

Intra vesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of the bladder: Final results

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5078-5078
Author(s):  
A. Bounedjar ◽  
R. Ferhat ◽  
F. Smaili ◽  
K. Bouzid
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Bladder Carcinoma ◽  
Performance Status ◽  
Single Agent ◽  
Transitional Cell ◽  
Hot Flashes ◽  
Haematological Toxicity ◽  
Urinary Cytology ◽  
Bcg Therapy

5078 Background: Systemic intravenous G is usually used in advanced bladder carcinoma. A phase I study of intravesical G has shown safety profile in pts refractory to BCG therapy (Dalbani G et al JCO 2002; 20:3193–98). In this study we evaluate the toxicity and the efficacy of intravesical G in patients (pts) with superficial bladder carcinoma. Methods: The study population criteria were: age = 18 years old, histological diagnosis of transitional cell carcinoma (TCC) of bladder (Cis and pT1) confirmed by transurethral resection (TUR), no prior chemotherapy, a performance status (PS) < 2, good bone marrow reserve, adequate renal and liver function and informed consent. Three weeks after a total TUR, pts receive intravesical instillation of 2,000 mg G every wk for 6 wks, than every month for six months. Evaluation is performed 3–4 wks after the last instillation (CT scan and/or US pelvis, urinary cytology and cystoscopy with biopsy). Results: From February 2003 to June 2004, 60 pts (57M/3F) were enrolled in the study (M/F = 57/3). The median age was 59,5 years old (24–84). Nine pts had a carcinoma in situ (Cis) and 51 had pT1 lesions. They received a total of 720 instillations. All pts were evaluable for toxicity and response Toxicity (CTC/NCI scale) is evaluated over the 720 instillations. Non haematological toxicity was grade 1: irritate bladder reaction (4.7%), asthenia (2.9%), nausea and vomiting (1.8%) and hot flashes (2%). Grade 1 haematological toxicity: anaemia (6.8%), leucopenia (4.5%) and thrombocytopenia (0.4%). After a follow-up time of 30 to 48 months, all pts were evaluable for tumor response: 53 patient had a persistant complete remission after TUR. Five patients (8.3%) had a superficial relapse of TCC (one at six months, 2 at 9 months and 2 others at 12 months). Two patients had progressive disease at 18 months and 27 months. Conclusion: Intravesical G is an active and well tolerated treatment even after repeated instillation in pts with superficial TCC carcinoma of the bladder. No significant financial relationships to disclose.

Clinical evaluation of nuclear matrix protein 22 as urinary marker of transitional cell carcinoma of bladder

2008 ◽  
Vol 75 (1) ◽  
pp. 20-23
Author(s):  
R.F. Liotta ◽  
F. Mangiapia ◽  
M.L. Tarantino ◽  
S. Di Meo ◽  
V. Mirone ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Tumor Marker ◽  
Cell Carcinoma ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Transitional Cell ◽  
Cancer Surveillance ◽  
Urinary Cytology ◽  
Nuclear Matrix Protein

Objectives. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. Materials and Methods. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 test before the cystoscopy. All samples were processed according to the instructions provided with the manufacturer's kit instructions. Results. 12 cases of TCC recurrences were detected with biopsy. Cystoscopy was positive in 8 cases, NMP22 test was positive in 11 cases, and in only one case the cytopathology yielded positive results. In 14 cases NMP22 resulted as false positive. Conclusions. Urinary NMP22 appeared to be a potential tumor marker for detecting TCC of the bladder, which might rise the sensitivity of cystoscopy especially in high-grade cancer surveillance more than cytology might do.

Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder

2006 ◽  
Vol 97 (5) ◽  
pp. 997-1001 ◽  
Author(s):  
PIERRE I. KARAKIEWICZ ◽  
SERGE BENAYOUN ◽  
CRAIG ZIPPE ◽  
GERSON LUDECKE ◽  
HANS BOMAN ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Urinary Cytology ◽  
Carcinoma Of The Bladder

Preliminary comparative considerations about urinary cytology and the Bard BTA test in the diagnosis and follow-up of superficial bladder cancer

1995 ◽  
Vol 62 (1_suppl) ◽  
pp. 88-90
Author(s):  
C. Boccafoschi ◽  
F. Montefiore ◽  
S. Treffiletti ◽  
D. Signorello ◽  
A. Langé
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Bladder Tumour ◽  
Transitional Cell ◽  
Latex Agglutination ◽  
Urinary Cytology ◽  
In Vitro Test ◽  
Carcinoma Of The Bladder

— The value of urinary cytology in the diagnosis and follow-up of superficial transitional cell carcinoma of the bladder is well known. Results of traditional cytologic examinations may be affected by the different methods of urine collection, preservation, manipulation and observation of the samples so that more objective tools are desirable. The aim of this study in to compare the traditional cytologic examinations with a new diagnostic in-vitro test (Bard BTA test), which can detect antigen complexes in the urine due to the contact of the tumour cells with the basement membrane. The Bard BTA test is a latex agglutination assay which identifies the bladder tumour antigens in the urine. The result of the agglutination reaction (positive or negative) may be visually distinguished by the variation in colour of special strips of testing paper. The Authors report on a preliminary experience in the follow-up of patients with previous superficial transitional cell carcinoma of the bladder: they compare the results of traditional cytology, the Bard BTA test and cystoscopy and have found agreement in 70% of the cases.

Sign in / Sign up

Export Citation Format

Share Document